Company profile
IOVANCE BIOTHERAPEUTICS, INC.
NASDAQ:IOVABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ALDESLEUKIN | approved | — | 0 | — |
| Lifileucel | approved | — | 10 | approved |
| IOV-2001 | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07743723 | phase1_2 | not_yet_recruiting | 2026-08-01 | 2034-03-01 | Iovance Biotherapeutics, Inc. | A Study of IOV-5001 in Adults With Advanced Solid Tumors |
| NCT06481592 | phase2 | recruiting | 2024-10-29 | 2028-05-01 | Iovance Biotherapeutics, Inc. | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. |
| NCT07288203 | phase2 | active_not_recruiting | 2025-11-28 | 2032-12-01 | Iovance Biotherapeutics, Inc. | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma |
| NCT07741877 | phase2 | not_yet_recruiting | 2026-09-01 | 2033-09-01 | Iovance Biotherapeutics, Inc. | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma |
| NCT05361174 | phase1_2 | recruiting | 2022-07-20 | 2027-09-01 | Iovance Biotherapeutics, Inc. | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 103293 | BLA | Iovance Biotherapeutics Manufacturing LLC | ||||
Loading… | ||||||
| BLA 125773 | BLA | Iovance Biotherapeutics, Inc. | ||||
Loading… | ||||||